🫧 Edgar looked up BRISTOL-MYERS SQUIBB COMPANY ($BMY). Last filing: 10-Q, 2026-07-30. 9 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $48.2B (FY2025), total debt $44.8B. Experience: revenue down 0.2% on the year, up 1.0% a year over 4 years. Soundness: equity 20.5% of assets, return on equity 38.2%, payout 71.5% of profit, dividend per share up 18 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $43.5B and $50.6B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; on a year the method never saw, 83.4% landed inside). In a shock year the stress range is $40.7B to $53.8B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): growth -0.2% against 13.7%.
Gold is paid out to shareholders; navy is kept in the business. Retained profit times return on equity is the pace a company can fund from itself. Facts from the filings, not a recommendation.
| Fiscal year end | 2025-12-31 |
| Revenue | $48.2B |
| Revenue, on the year | −0.2% |
| Revenue, a year over the record | 1.0% |
| Operating margin | — |
| Operating margin, prior year | — |
| Net margin | 14.6% |
| Research and development | $10.0B · 20.6% of revenue |
| Total debt | $44.8B |
| Equity of assets | 20.5% |
| Return on equity | 38.2% |
| Payout of profit | 71.5% |
| Dividend per share | $2.49 · up 18 years running |
| Earnings per share | $3.47 |
| Book value per share | $9.06 |
| Revenue per share | $23.64 |
| Shares outstanding | 2,039,000,000 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Quiet: none of the watched events (late-filing notices, bankruptcy, listing notices, debt triggers, non-reliance, auditor changes, restructuring, impairment, cyber incidents, leadership changes) filed in the last 12 months.
Sailing speed follows growth: 1.5% a year crosses the harbor in 76 seconds.
No warning signs on the measures below.
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Both views must agree for a label · market view (price) not sourced; add a price at /boards/ask.json?q=TICKER&price=… · a description, not advice.
| Cash conversion (operating cash ÷ revenue) | 29.4% |
| Growth speed (3 years, per year) | 1.5% |
| Revenue swing (std-dev of yearly growth) | 4.2% |
| Cash flow (operating · investing · financing · free) | $14.2B · −$4.1B · −$10.3B · $12.8B |
| Investment book (cash · short-term · long-term) | $10.2B · $464M · $396M |
| Common dividend | paid, raised on the year |
| Equity of assets | 20.5% |
Bristol-Myers Squibb is growing slower than its size class, with steadier revenue. SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company
Or tap watch on any row above. One note the day they file, from Edgar, each with a one-click stop link. Handled to EU GDPR and Japan APPI standards.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time (757) 390-0424Nine boards reading every SEC filing the day it lands, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.